Epigenetic silencing of ZBTB28 promotes renal cell carcinogenesis

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Zinc finger and BTB domain-containing protein 28 (ZBTB28) shows potential as a tumor suppressor in various cancers.
• The epigenetic regulation and specific functions of ZBTB28 in renal cell carcinoma (RCC) are not well understood.

Purpose of the Study:

• To investigate the epigenetic silencing of ZBTB28 in RCC.
• To elucidate the functional role of ZBTB28 in RCC cell proliferation, migration, and apoptosis.
• To explore ZBTB28 as a potential therapeutic target for RCC.

Main Methods:

• Semi-quantitative reverse transcription polymerase chain reaction (PCR) was used to analyze ZBTB28 mRNA expression in RCC cell lines and normal kidney tissues.
• Methylation-specific PCR assessed ZBTB28 promoter methylation status in RCC cell lines, primary tumors, and adjacent normal tissues.
• Functional assays examined the effects of ZBTB28 on cell proliferation, migration, and apoptosis, alongside analyses of oncogenic signaling pathways.

Main Results:

• ZBTB28 promoter hypermethylation was observed in 88.9% of RCC cell lines, correlating with reduced ZBTB28 mRNA expression.
• Promoter methylation was detected in 73.5% of primary RCC tissues versus 7.1% in normal tissues, and was reversible by DNA methyltransferase inhibitors.
• ZBTB28 overexpression significantly suppressed RCC cell proliferation and migration, induced apoptosis, and inhibited oncogenic signaling pathways.

Conclusions:

• ZBTB28 is frequently epigenetically silenced via promoter methylation in RCC pathogenesis.
• ZBTB28 acts as a novel tumor suppressor gene in renal cell carcinoma.
• ZBTB28 represents a potential therapeutic target for developing novel RCC treatment strategies.